Efficient Research and Development through Co-Development
First written in FY2017-Q1. 12 of 21 entries say "Restated". Latest entry: 2026-03-23.
The whole theme swung hardest in 2022: 1 of 7 companies on the "Worse" side.
6 other companies' latest entry also says "Advanced".
- 2026-03-23AdvancedOther Disclosures
「Through this agreement, Kyorin Pharmaceutical and UBE aim to deliver new treatment options at an early stage to patients for whom existing drugs do not provide sufficient efficacy by combining UBE’s original compounds with Kyorin Pharmaceutical’s research and development expertise.」
Collaborative development and licensing with an external company progressed to execution of an agreement with UBE concerning a novel drug candidate compound. - FY2023-Q3AdvancedAnnual report
「In expanding its development pipeline during the third quarter of the fiscal year, Kyorin Pharmaceutical Co., Ltd. entered into an agreement with Susemed Co., Ltd. in November 2022 for the joint research and development and sale of a therapeutic app in the field of otolaryngology.」
Regarding R&D through joint development and sales with another company, the company progressed to signing an agreement with サスメド for a treatment application in the otolaryngology field. - FY2023-Q1AdvancedAnnual report
「杏林製薬㈱ entered into a Joint Development and Implementation Rights License Agreement with セルジェンテック㈱ (head office: Chiba, Chiba Prefecture) in May 2022 concerning regenerative medicine products using genetically modified human adipocytes for the treatment of Fabry disease,」
Regarding R&D through joint development with an external company, the company progressed to signing an agreement with セルジェンテック for a regenerative medicine product for Fabry disease. - FY2022-Q3RestatedAnnual report
「杏林製薬㈱ adds open innovation with domestic and overseas pharmaceutical companies, academia and venture companies to its in-house drug discovery,」
We continue R&D combining collaboration with external pharmaceutical companies, academia and venture companies. - FY2022-Q2RestatedAnnual report
「杏林製薬㈱ adds open innovation with domestic and overseas pharmaceutical companies, academia and venture companies to its in-house drug discovery,」
We continue R&D combining collaboration with external pharmaceutical companies, academia and venture companies. - FY2022-Q1RestatedAnnual report
「杏林製薬㈱ is working to invigorate its drug discovery platform by adding open innovation with domestic and overseas pharmaceutical companies, academia and venture companies to in-house drug discovery,」
We continue to pursue a policy of combining in-house drug discovery with open innovation involving external pharmaceutical companies, academia and venture companies. - FY2021-Q3RestatedAnnual report
「By adding open innovation with domestic and overseas pharmaceutical companies, academia and venture companies to in-house drug discovery,」
We continue R&D combining collaboration with external pharmaceutical companies, academia and venture companies. - FY2021-Q2AdvancedAnnual report
「As part of efforts to expand the development pipeline, in September of the same year we entered into an agreement with あすか製薬㈱ covering the joint development and sale of AKP-009, a treatment for benign prostatic hyperplasia, and acquired the rights to jointly develop and sell the drug in Japan.」
Regarding greater R&D efficiency through joint development and sales with another company, the company progressed to signing the AKP-009 agreement with あすか製薬 and acquiring the rights in Japan. - FY2021-Q1RestatedAnnual report
「By adding open innovation with domestic and overseas pharmaceutical companies, academia and venture companies to in-house drug discovery,」
We continue R&D combining collaboration with external pharmaceutical companies, academia and venture companies. - FY2020-Q3RestatedAnnual report
「By adding open innovation with domestic and overseas pharmaceutical companies, academia and venture companies to in-house drug discovery,」
We continue R&D through collaboration with pharmaceutical companies, academia and venture companies. - FY2020-Q1RestatedAnnual report
「By adding open innovation with domestic and overseas pharmaceutical companies, academia and venture companies to in-house drug discovery,」
We continue R&D through collaboration with external pharmaceutical companies, academia and venture companies. - FY2019Cited as achievedAnnual report
「In drug discovery research, as part of its open innovation activities, 杏林製薬㈱ began joint research this fiscal year with the Institute of Microbial Chemistry of the Microbial Chemistry Research Foundation,」
The start of joint research with the Institute of Microbial Chemistry is cited as the fiscal year's R&D achievement through collaboration with an external institution. - FY2019-Q3AdvancedAnnual report
「In drug discovery research, as part of our open innovation activities, we entered into a strategic partnership with Yissum, the technology transfer company of the Hebrew University of Jerusalem, in December 2018 for the creation of therapeutics for respiratory diseases.」
Regarding collaboration with external institutions, the company progressed to entering into a strategic partnership with Yissum for the creation of therapeutics for respiratory diseases. - FY2019-Q2AdvancedAnnual report
「As part of its open innovation activities in drug discovery research, 杏林製薬㈱ began joint research this fiscal year with the Institute of Microbial Chemistry of the Microbial Chemistry Research Foundation.」
Regarding collaboration with external research institutions, the company moved to the stage of launching joint research with the Institute of Microbial Chemistry this fiscal year. - FY2018RestatedAnnual report
「In drug discovery research, as part of our open innovation activities, we established the Respiratory Disease Drug Discovery Research Chair jointly with Kyoto University in April 2017 and began joint research.」
We continue to collaborate with external institutions through the joint research chair with Kyoto University. - FY2018-Q2RestatedAnnual report
「In drug discovery research, as part of our open innovation activities, we established the Respiratory Disease Drug Discovery Research Chair jointly with Kyoto University in April 2017 and began joint research.」
We continue to collaborate with external institutions through the joint research chair with Kyoto University. - FY2018-Q1AdvancedAnnual report
「As part of its open innovation efforts, the company established a joint research course with Kyoto University in April 2017 and began joint research.」
Regarding collaboration with external organizations, the company advanced to the concrete stage of establishing a joint research course with Kyoto University and beginning joint research. - FY2017RestatedAnnual report
「The company will continue to pursue efficient and active R&D activities, including focusing on specific areas and collaborating with other pharmaceutical companies and academia.」
The company continues to improve R&D efficiency by focusing on priority areas and collaborating with external organizations. - FY2017-Q3RestatedAnnual report
「The company will continue to pursue efficient and active R&D activities, including focusing on specific areas and collaborating with other pharmaceutical companies.」
The company continues to improve R&D efficiency by focusing on priority areas and collaborating with other pharmaceutical companies. - FY2017-Q2RestatedAnnual report
「The company worked to conduct efficient R&D activities, including by advancing joint development with other pharmaceutical companies.」
The company continues to improve R&D efficiency through joint development with other companies. - FY2017-Q1First statedAnnual report
「We worked to conduct efficient research and development activities, including by pursuing co-development with other pharmaceutical companies.」
Co-development with other pharmaceutical companies is identified as a means of improving R&D efficiency.